Last Update 04 Mar 26

Fair value Increased 0.24%

TEVA: Affordable Medicines And 2026 Pipeline Catalysts Will Drive Bullish Outlook

Analysts have nudged their price target for Teva Pharmaceutical Industries up to $38 from $37, reflecting a slightly higher fair value estimate and updated assumptions around long term revenue growth, margins, and the potential for duvakitug to reach $3b in peak sales following recent Phase 2 data with Sanofi.

Analyst Commentary

Recent research updates on Teva Pharmaceutical Industries highlight a mix of enthusiasm around the pipeline and affordability theme, alongside caution around execution risk and legal overhangs.

Bullish Takeaways

Bullish analysts are lifting price targets into the mid to high US$30s, with one high end view at US$40. They link this to a higher assessed fair value, as duvakitug is modeled at about US$3b in potential peak sales.
The RELIEVE UCCD Phase 2 maintenance data for duvakitug is feeding directly into higher assumed peak revenue. This supports slightly richer multiples in some models and underpins the recent upward tweaks to targets.
Several bullish analysts frame Teva as a key way to gain exposure to an affordability theme in medicines heading into 2026. They see this theme as supportive for the company’s ability to sustain its position in key markets.
Some research highlights 2026 as an important year for the pipeline. There is an expectation that R&D productivity could start to be reflected more clearly in valuations if upcoming catalysts meet internal assumptions.

Bearish Takeaways

The court ruling that Teva’s generic Korlym does not infringe Corcept’s patents confirms Teva’s ability to participate in the Cushing’s syndrome market. It also underscores ongoing legal and competitive complexities that can affect earnings quality.
Bearish analysts, or those keeping a more cautious stance, may point out that higher targets are still sensitive to execution on the R&D story, especially the need to convince investors that the pipeline can sustain value beyond 2026.
The uplift in targets tied to duvakitug assumes successful progression and commercial execution. Any delay or weaker than modeled uptake could weigh on how quickly the current fair value estimates are reflected in the market.
While price targets are higher, the repeated focus on a few flagship assets means Teva’s story remains concentrated. Any setback around these products could have an outsized impact on sentiment and valuation.

What’s in the News

Sanofi and Teva reported positive long term extension data from the RELIEVE UCCD study of duvakitug in ulcerative colitis and Crohn’s disease, with clinical remission and endoscopic response maintained over 44 weeks and a safety profile consistent with the earlier Phase 2b induction study (Key Developments).
Teva issued 2026 revenue guidance in a range of US$16.4 million to US$16.8 million, setting a specific topline target for investors to track (Key Developments).
Teva outlined earnings guidance through 2030, including expectations for flat to slightly lower revenues in 2026 versus 2025 with higher operating profit, low single digit revenue growth in 2027 with a 30% increase in operating profit over 2026, and a mid single digit revenue CAGR from 2026 to 2030 with operating profit more than 30% above 2026 (Key Developments).
Teva and partner Medincell submitted a New Drug Application to the U.S. FDA for TEV-749 / mdc-TJK, an olanzapine extended release injectable suspension for once monthly treatment of schizophrenia in adults, aiming to support treatment adherence and stability for a broad patient group (Key Developments).
Media coverage has highlighted how drugmakers, including companies like Teva, are using AI tools to help with clinical trials and regulatory submissions, adding attention to how larger pharma groups are handling development timelines and costs (Reuters).

Valuation Changes

Fair Value: adjusted from $37.95 to $38.05, a slight upward change in the modeled estimate.
Discount Rate: remains at 8.45%, indicating no change in the assumed risk profile.
Revenue Growth: reduced from 1.32% to 1.23%, a modest decrease in the long term growth assumption.
Net Profit Margin: increased from 13.44% to 13.48%, a small improvement in expected profitability.
Future P/E: revised from 23.23x to 23.28x, reflecting a very small change in the valuation multiple applied to earnings.

5 views

Key Takeaways

Teva's diversified portfolio and expanding branded and biosimilar products are expected to drive steady, higher-margin growth and profitability amid demographic and regulatory tailwinds.
Operational efficiencies, modernization, and a resilient generics platform are strengthening Teva's financial foundation, supporting income growth, free cash flow, and debt reduction.
Heavy dependency on select branded drugs, ongoing debt constraints, and heightened regulatory and competitive risks threaten sustainable growth and margin improvement.

Catalysts

About Teva Pharmaceutical Industries

Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.What are the underlying business or industry changes driving this perspective?

Ongoing demographic shifts toward an aging global population and rising healthcare awareness in emerging markets are expanding long-term demand for branded medicines, generics, and biosimilars, positioning Teva's diversified portfolio for steady revenue growth.
Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.
The accelerating launch cadence of biosimilars (with 8 launches targeted through 2027 and a goal to double biosimilar revenue), backed by favorable regulatory trends increasing biosimilar adoption in major markets, should unlock incremental, higher-margin revenue streams and offset headwinds from traditional generics, powering long-term EBITDA growth.
Cost-containment initiatives and portfolio transformation (including $700 million in targeted operational savings and modernization) are structurally reducing Teva's expense base, driving sustainable operating income growth and improved free cash flow, while strengthening the balance sheet and supporting deleveraging.
Teva's stable and resilient generics platform, with robust upcoming launches of complex generics in the US/EU and continued demand supported by payer incentives for generic substitution, provides a predictable baseline for revenues and supports the company's ability to absorb volatility in legacy products, underpinning confidence in medium-term earnings visibility.

Teva Pharmaceutical Industries Earnings and Revenue Growth

Teva Pharmaceutical Industries Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Teva Pharmaceutical Industries's revenue will grow by 2.3% annually over the next 3 years.
Analysts assume that profit margins will increase from -0.9% today to 8.2% in 3 years time.
Analysts expect earnings to reach $1.5 billion (and earnings per share of $1.26) by about September 2028, up from $-157.0 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 24.4x on those 2028 earnings, up from -137.1x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 19.5x.
Analysts expect the number of shares outstanding to grow by 1.24% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.34%, as per the Simply Wall St company report.

Teva Pharmaceutical Industries Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The company's generics segment, historically its core business, is expected to deliver only flat or low single-digit growth through 2027, with management attributing weak performance to prior year volatility, competitive pressures, delayed generic launches, and increased competition, which may result in stagnant revenues from this segment long-term.
Long-term reliance on a small number of innovative branded drugs (AUSTEDO, AJOVY, UZEDY) for growth is a risk, particularly as the company faces upcoming price negotiations under the Inflation Reduction Act (IRA) that could materially reduce net pricing and margins on AUSTEDO, impacting both revenue and net margin.
Heavy debt load remains a structural risk with net debt over $15 billion and a net debt/EBITDA ratio just above 3x, which could limit the ability to invest in R&D/business development and put ongoing pressure on earnings and free cash flow until further deleveraging occurs.
Uncertainty around global trade and regulatory environments-such as evolving pharmaceutical tariffs in Europe and the U.S. and lingering ambiguity over which products/generics are included or excluded-could inflict unforeseen cost pressures or disrupt supply chains, leading to margin compression or revenue disruption.
The pipeline's projected peak sales and biosimilar expansion are subject to execution risk, including potential delays, regulatory setbacks, or slower-than-expected adoption versus entrenched competitors and new entrants, possibly stalling topline growth, and eroding anticipated improvements in operating margin and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $23.556 for Teva Pharmaceutical Industries based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $29.0, and the most bearish reporting a price target of just $18.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $17.8 billion, earnings will come to $1.5 billion, and it would be trading on a PE ratio of 24.4x, assuming you use a discount rate of 8.3%.
Given the current share price of $18.76, the analyst price target of $23.56 is 20.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Teva Pharmaceutical Industries?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries